Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dawes Fretzin Dermatology Group
mi
from
Indianapolis, IN
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dawes Fretzin Dermatology Group
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
The Indiana Clinical Trials Center, PC
mi
from
Plainfield, IN
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
The Indiana Clinical Trials Center, PC
mi
from
Plainfield, IN
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
DS Research
mi
from
Louisville, KY
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
DS Research
mi
from
Louisville, KY
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Shondra L. Smith, MD Dermatology & Advanced Aesthetics
mi
from
Lake Charles, LA
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Shondra L. Smith, MD Dermatology & Advanced Aesthetics
mi
from
Lake Charles, LA
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Somerset Skin Centre
mi
from
Troy, MI
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Somerset Skin Centre
mi
from
Troy, MI
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Consortium
mi
from
Las Vegas, NV
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Consortium
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Psoriasis Treatment Center of Central New Jersey
mi
from
East Windsor, NJ
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Psoriasis Treatment Center of Central New Jersey
mi
from
East Windsor, NJ
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
The Dermatology Group, P.C.
mi
from
Verona, NJ
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
The Dermatology Group, P.C.
mi
from
Verona, NJ
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Forest Hills Dermatology Group
mi
from
Forest Hills, NY
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Forest Hills Dermatology Group
mi
from
Forest Hills, NY
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Sadick Research Group
mi
from
New York, NY
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Sadick Research Group
mi
from
New York, NY
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Vital Prospects Clinical Research Institute, P.C.
mi
from
Tulsa, OK
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Vital Prospects Clinical Research Institute, P.C.
mi
from
Tulsa, OK
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
DermDox Centers for Dermatology
mi
from
Hazleton, PA
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
DermDox Centers for Dermatology
mi
from
Hazleton, PA
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Clinical Partners, LLC
mi
from
Johnston, RI
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Clinical Partners, LLC
mi
from
Johnston, RI
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Health Concepts
mi
from
Rapid City, SD
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Health Concepts
mi
from
Rapid City, SD
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Bellaire Dermatology Associates
mi
from
Bellaire, TX
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Bellaire Dermatology Associates
mi
from
Bellaire, TX
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Texas Dermatology and Laser Specialists
mi
from
San Antonio, TX
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Texas Dermatology and Laser Specialists
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
West End Dermatology Associates
mi
from
Richmond, VA
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
West End Dermatology Associates
mi
from
Richmond, VA
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
TCR Medical Corporation
mi
from
San Diego, CA
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
TCR Medical Corporation
mi
from
San Diego, CA
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
UPMC Department of Dermatology
mi
from
Pittsburgh, PA
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
UPMC Department of Dermatology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
University of Connecticut Health Center (UConn Health)
mi
from
Farmington, CT
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
University of Connecticut Health Center (UConn Health)
mi
from
Farmington, CT
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
MediSearch Clinical Trials
mi
from
Saint Joseph, MO
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
MediSearch Clinical Trials
mi
from
Saint Joseph, MO
Click here to add this to my saved trials
Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris
A Phase 1, Single-center, Open-label Pharmacokinetic, Safety and Tolerability Study of SB204 in Adolescents With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
WCCT #1
mi
from
Austin, TX
Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris
A Phase 1, Single-center, Open-label Pharmacokinetic, Safety and Tolerability Study of SB204 in Adolescents With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
WCCT #1
mi
from
Austin, TX
Click here to add this to my saved trials
Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa
A Phase 2 Open-label Single Center Study to Evaluate the Efficacy of Apremilast for the Treatment of Moderate Hidradenitis Suppurativa
Status: Enrolling
Updated:  12/31/1969
Florida Academic Dermatology Centers
mi
from
Coral Gables, FL
Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa
A Phase 2 Open-label Single Center Study to Evaluate the Efficacy of Apremilast for the Treatment of Moderate Hidradenitis Suppurativa
Status: Enrolling
Updated: 12/31/1969
Florida Academic Dermatology Centers
mi
from
Coral Gables, FL
Click here to add this to my saved trials
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated:  12/31/1969
Center for Dermatology Clinical Research
mi
from
Fremont, CA
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated: 12/31/1969
Center for Dermatology Clinical Research
mi
from
Fremont, CA
Click here to add this to my saved trials
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated:  12/31/1969
eStudy Site
mi
from
La Mesa, CA
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated: 12/31/1969
eStudy Site
mi
from
La Mesa, CA
Click here to add this to my saved trials
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated:  12/31/1969
Palmtree Clinical Research Inc
mi
from
Palm Springs, CA
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated: 12/31/1969
Palmtree Clinical Research Inc
mi
from
Palm Springs, CA
Click here to add this to my saved trials
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated:  12/31/1969
Horizons Clinical Research Center, LLC
mi
from
Denver, CO
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated: 12/31/1969
Horizons Clinical Research Center, LLC
mi
from
Denver, CO
Click here to add this to my saved trials
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated:  12/31/1969
Clinical Research of South Florida
mi
from
Coral Gables, FL
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated: 12/31/1969
Clinical Research of South Florida
mi
from
Coral Gables, FL
Click here to add this to my saved trials
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated:  12/31/1969
International Dermatology Research, Inc.
mi
from
Miami, FL
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated: 12/31/1969
International Dermatology Research, Inc.
mi
from
Miami, FL
Click here to add this to my saved trials
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated:  12/31/1969
Compass Research LLC
mi
from
Orlando, FL
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated: 12/31/1969
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated:  12/31/1969
Forward Clinical Trials
mi
from
Tampa, FL
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated: 12/31/1969
Forward Clinical Trials
mi
from
Tampa, FL
Click here to add this to my saved trials
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated:  12/31/1969
Palm Beach Research Center
mi
from
West Palm Beach, FL
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated: 12/31/1969
Palm Beach Research Center
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated:  12/31/1969
Minnesota Clinical Study Center
mi
from
Fridley, MN
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated: 12/31/1969
Minnesota Clinical Study Center
mi
from
Fridley, MN
Click here to add this to my saved trials
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated:  12/31/1969
Dermatology and Laser Center of Charleston
mi
from
Charleston, SC
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated: 12/31/1969
Dermatology and Laser Center of Charleston
mi
from
Charleston, SC
Click here to add this to my saved trials
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated:  12/31/1969
Institute of Clinical Research - Tennessee, LLC
mi
from
Murfreesboro, TN
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated: 12/31/1969
Institute of Clinical Research - Tennessee, LLC
mi
from
Murfreesboro, TN
Click here to add this to my saved trials
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated:  12/31/1969
J&S Studies
mi
from
College Station, TX
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated: 12/31/1969
J&S Studies
mi
from
College Station, TX
Click here to add this to my saved trials
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated:  12/31/1969
The Center for Skin Research
mi
from
Houston, TX
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated: 12/31/1969
The Center for Skin Research
mi
from
Houston, TX
Click here to add this to my saved trials
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated:  12/31/1969
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated: 12/31/1969
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated:  12/31/1969
Dermatology Clinical Research Center
mi
from
San Antonio, TX
A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Status: Enrolling
Updated: 12/31/1969
Dermatology Clinical Research Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fort Smith, AR
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Ramon, CA
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Ramon, CA
Click here to add this to my saved trials
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Clearwater, FL
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Clearwater, FL
Click here to add this to my saved trials
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
North Miami Beach, FL
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
North Miami Beach, FL
Click here to add this to my saved trials
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Plainfield, IN
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Plainfield, IN
Click here to add this to my saved trials
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Joseph, MO
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Joseph, MO
Click here to add this to my saved trials
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Albuquerque, NM
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Warwick, RI
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Warwick, RI
Click here to add this to my saved trials